Information about Viramune XL (Nevirapine ER)
Viramune XL (Nevirapine ER) is an extended-release formulation of Nevirapine, a non-nucleoside reverse transcriptase inhibitor (NNRTI) used to treat HIV-1 infection. The extended-release (ER) formulation allows for once-daily dosing, which can improve convenience for patients compared to the immediate-release version, which requires more frequent dosing. Like other NNRTIs, Nevirapine works by inhibiting the reverse transcriptase enzyme, which is essential for HIV replication.
Product Highlights
- Viramune XL is primarily used to treat HIV-1 infection in adults and children (when appropriate).
- It is often used as part of a combination antiretroviral therapy (cART) to control viral replication and reduce the viral load in HIV-positive individuals.
Key Ingredient
Key Benefits
- The extended-release formulation enables once-daily dosing, which can help improve patient adherence to the treatment plan.
- Nevirapine helps lower the amount of HIV in the bloodstream, reducing the risk of HIV progression to AIDS and improving immune function.
- By suppressing HIV replication, Viramune XL helps reduce the chances of transmitting the virus to others, particularly when used in combination with other preventive measures.
- By controlling the virus, the medication helps maintain immune system health and improves overall quality of life for people with HIV.
Direction of Use
- The typical starting dose is 400 mg once daily, but the healthcare provider may adjust this based on individual patient needs and health conditions.
- Viramune XL should be taken orally, with or without food. The tablets should be swallowed whole and not chewed, split, or crushed.
- It’s important to take the medication exactly as prescribed and at the same time each day to help with adherence and optimal effectiveness.
- Viramune XL should always be used in combination with other antiretroviral drugs to prevent the development of drug resistance.
Safety Concerns
- Nevirapine can cause serious liver damage. Liver function tests should be monitored closely, particularly during the first 18 weeks of therapy. Severe liver problems can occur, and they may be more common in certain individuals, such as those with pre-existing liver disease.
- A common side effect of Nevirapine is skin rash. In some cases, it can progress to severe reactions such as Stevens-Johnson Syndrome, which can be life-threatening. Patients should report any rash immediately.
- Some individuals may experience hypersensitivity reactions, including fever, joint pain, and swollen lymph nodes. These reactions should be reported to a healthcare provider.
- Nevirapine interacts with various other medications, including certain contraceptives and other HIV medications. It is essential to inform the healthcare provider of all medications being taken to avoid interactions.
- Some individuals may experience side effects like dizziness, headache, or fatigue. These should be monitored.
Avoid Viramune XL (Nevirapine ER) If
- Do not use in patients with moderate to severe hepatic impairment due to the risk of liver toxicity.
- Viramune XL should not be used in individuals who have had hypersensitivity reactions, including severe skin reactions like Stevens-Johnson Syndrome, to Nevirapine or similar drugs in the NNRTI class.
- Patients with active hepatitis or those with a history of chronic liver disease should not take Viramune XL.
- Viramune XL may be contraindicated during pregnancy, particularly in the first trimester, due to the risk of liver toxicity. It should be used carefully and with close medical supervision.
- If there is a known allergy to Nevirapine or other NNRTIs, Viramune XL should be avoided.
